128 related articles for article (PubMed ID: 34942295)
1. Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review.
Croitoru D; Nathanielsz N; Seigel K; Elsawi R; Sibbald C; Alavi A; Zipursky J; Piguet V
J Am Acad Dermatol; 2022 Sep; 87(3):655-656. PubMed ID: 34942295
[No Abstract] [Full Text] [Related]
2. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis.
Aggarwal P
Dermatol Ther; 2020 Mar; 33(2):e13221. PubMed ID: 31925868
[TBL] [Abstract][Full Text] [Related]
3. Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy.
Dixit S; Selva-Nayagam P; Hamann I; Fischer G
J Low Genit Tract Dis; 2015 Jan; 19(1):e6-9. PubMed ID: 24769650
[TBL] [Abstract][Full Text] [Related]
4. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia.
Montoto S; Bosch F; Estrach T; Blade J; Nomdedeu B; Nontserrat E
Leuk Lymphoma; 1998 Jun; 30(1-2):199-202. PubMed ID: 9669691
[TBL] [Abstract][Full Text] [Related]
5. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy.
Lewerin C; Mobacken H; Nilsson-Ehle H; Swolin B
Leuk Lymphoma; 1997 Aug; 26(5-6):629-32. PubMed ID: 9389372
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary pyoderma gangrenosum without cutaneous manifestations.
Sakata KK; Penupolu S; Colby TV; Gotway MB; Wesselius LJ
Clin Respir J; 2016 Jul; 10(4):508-11. PubMed ID: 25354722
[TBL] [Abstract][Full Text] [Related]
7. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.
Jin K; Matsuzaki Y; Akasaka E; Nakano H; Sawamura D
J Dermatol; 2019 Mar; 46(3):e108-e109. PubMed ID: 30192400
[No Abstract] [Full Text] [Related]
8. Pyoderma gangrenosum of the scalp following hair highlights in a postpartum patient.
Gorpelioglu C; Sarifakioglu E
Eur J Dermatol; 2008; 18(1):97-8. PubMed ID: 18086612
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.
Benzaquen M; Monnier J; Beaussault Y; Rouby F; Berbis P
Australas J Dermatol; 2017 Nov; 58(4):e270-e271. PubMed ID: 28660635
[No Abstract] [Full Text] [Related]
10. A case of cabozantinib-induced pyoderma gangrenosum-like ulceration.
Matsudate Y; Ninomiya I; Sadamoto Y
Australas J Dermatol; 2023 Feb; 64(1):154-155. PubMed ID: 36305613
[No Abstract] [Full Text] [Related]
11. Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab.
Murthy RK; Jackson J; Chatham WW; Sami N
J Clin Rheumatol; 2016 Oct; 22(7):393-5. PubMed ID: 27660945
[No Abstract] [Full Text] [Related]
12. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic.
Tinoco MP; Tamler C; Maciel G; Soares D; Avelleira JC; Azulay D
Int J Dermatol; 2008 Sep; 47(9):953-6. PubMed ID: 18937662
[TBL] [Abstract][Full Text] [Related]
13. Pyoderma gangrenosum-like lesions provocated by botulinum injections.
Owczarczyk-Saczonek A; Zdanowska N; Wańczyk-Dręczewska B; Wygonowska E; Placek W; Griffiths CC; Griffiths TW
Dermatol Ther; 2020 Mar; 33(2):e13227. PubMed ID: 31957116
[TBL] [Abstract][Full Text] [Related]
14. Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review.
Lytvyn Y; Mufti A; Maliyar K; Sachdeva M; Yeung J
Adv Skin Wound Care; 2022 Aug; 35(8):454-460. PubMed ID: 35293377
[TBL] [Abstract][Full Text] [Related]
15. ANCA positive propylthiouracil induced pyoderma gangrenosum.
Gungor K; Gonen S; Kisakol G; Dikbas O; Kaya A
J Endocrinol Invest; 2006 Jun; 29(6):575-6. PubMed ID: 16840840
[No Abstract] [Full Text] [Related]
16. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab.
Donmez S; Pamuk ON; Gedik M; A K R; Bulut G
Int J Rheum Dis; 2014 May; 17(4):471-5. PubMed ID: 24460826
[TBL] [Abstract][Full Text] [Related]
17. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
18. Onset of pyoderma gangrenosum after tocilizumab therapy for Takayasu arteritis: A new undescribed paradoxical reaction.
Borgia F; Sutera D; Spagnolo A; Mazza F; Bertino L; Cannavò SP; Gallizzi R
Br J Clin Pharmacol; 2021 Aug; 87(8):3378-3379. PubMed ID: 33567476
[No Abstract] [Full Text] [Related]
19. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
20. Pyoderma gangrenosum possibly triggered by adalimumab.
Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
